Zonación composicional en granates de la sierra de Pie de Palo, San Juan, Argentina: Implicancias en la historia metamórfica

Compositional zoning of garnet from two domains of the Sierra de Pie de Palo (Western Sierras Pampeanas) evidence contrasting tectono-metamorphic histories. Garnets from Grt-amphibolites of the underlaying Grenville-age mafic-ultramafic belt (Complejo de Pie de Palo) on the western side of the Sierra show two discontinuous zones, one internal (core) and one external (rim). These zones are separated by inclusions of quartz and plagioclase arranged concentrically. Each zone shows different composition and also different patterns of variation for each end-member. In contrast, garnets from the Neoproterozoic Ca-metapelites in the overlaying southeastern domain of the Sierra de Pie de Palo show a continuous compositional zoning, characteristic of a single stage of growth during the Famatinian orogeny (Ordovician). Alm, Prp and Grs increase regularly outwards while Sps shows a reverse pattern. Garnet chemistry is consistent with the existence of a polymetamorphic basement (Grenvillian + Famatinian metamorphism) on the western side and a younger monometamorphic sedimentary cover.Fil: Ramacciotti, C. Universidad Nacional de Córdoba. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigación en Ciencias de la Tierra; Argentina.Fil: Baldo, E. Universidad Nacional de Córdoba. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigación en Ciencias de la Tierra; Argentina.Fil: Casquet, C. Universidad Complutense. Instituto de Geociencias. Departamento de Petrología y Geoquímica; España.Fil: Colombo, F. Universidad Nacional de Córdoba. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigación en Ciencias de la Tierra; Argentina.Geologí

Edad U/Pb SHRIMP en circones detríticos al sureste de Pie de palo, San Juan, Argentina: Evidencias de sedimentación y magmatismo paleozoico en las Sierras Pampeanas Occidentales

Fil: Ramacciotti, C. Universidad Nacional de Córdoba. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigaciones en Ciencias de la Tierra; Argentina.Fil: Baldo, Edgardo G. Universidad Nacional de Córdoba. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigaciones en Ciencias de la Tierra; Argentina.Fil: Casquet, C. Universidad Complutense. Instituto de Geociencias. Departamento de Petrología y Geoquímica; España.Fil: Galindo, C. Universidad Complutense. Instituto de Geociencias. Departamento de Petrología y Geoquímica; España.Fil: Verdecchia, S. Universidad Nacional de Córdoba. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigaciones en Ciencias de la Tierra; Argentina.La Sierra de Pie de Palo consiste de un sistema de corrimientos de vergencia oeste, cuyas láminas están compuestas por un basamento mesoproterozoico (Casquet et al., 2001; Vujovich et al., 2004; Rapela et al., 2010) aflorante en el centro oeste de la sierra, una cobertera metasedimentaria denominada Secuencia Metasedimentaria Difunta Correa (SMDC) de edad neoproterozoica (Baldo et al., 1998; Galindo et al., 2004; Vujovich et al., 2004; Rapela et al., 2005) cuyos principales afloramientos se encuentran en el sureste de la sierra; y por último, en el sector más occidental afloran rocas correspondientes a una plataforma carbonáticasiliciclástica con un metamorfísmo de bajo grado sobreimpuesto, denominadas Grupo Caucete, el cual posee una edad neoproterozoica-cámbrica (por ej.: Galindo et al., 2004; Naipauer et al., 2010). Cabe destacar la presencia de un magmatismo anorogénico de 774 ± 6 Ma (Baldo et al., 2006) y un magmatismo de arco ordovícico (Pankhurst et al., 1998).Fil: Ramacciotti, C. Universidad Nacional de Córdoba. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigaciones en Ciencias de la Tierra; Argentina.Fil: Baldo, Edgardo G. Universidad Nacional de Córdoba. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigaciones en Ciencias de la Tierra; Argentina.Fil: Casquet, C. Universidad Complutense. Instituto de Geociencias. Departamento de Petrología y Geoquímica; España.Fil: Galindo, C. Universidad Complutense. Instituto de Geociencias. Departamento de Petrología y Geoquímica; España.Fil: Verdecchia, S. Universidad Nacional de Córdoba. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigaciones en Ciencias de la Tierra; Argentina.Geologí

Climacteric Lowers Plasma Levels of Platelet-Derived Microparticles: A Pilot Study in Pre-versus Postmenopausal Women

Background: Climacteric increases the risk of thrombotic events by alteration of plasmatic coagulation. Up to now, less is known about changes in platelet-(PMP) and endothelial cell-derived microparticles (EMP). Methods: In this prospective study, plasma levels of microparticles (MP) were compared in 21 premenopausal and 19 postmenopausal women. Results: No altered numbers of total MP or EMP were measured within the study groups. However, the plasma values of CD61-exposing MP from platelets/megakaryocytes were higher in premenopausal women (5,364 x 10(6)/l, range 4,384-17,167) as compared to postmenopausal women (3,808 x 10(6)/l, range 2,009-8,850; p = 0.020). This differentiation was also significant for the subgroup of premenopausal women without hormonal contraceptives (5,364 x 10(6)/l, range 4,223-15,916; p = 0.047; n = 15). Furthermore, in premenopausal women, higher plasma levels of PMP exposing CD62P were also present as compared to postmenopausal women (288 x 10(6)/l, range 139-462, vs. 121 x 10(6)/l, range 74-284; p = 0.024). This difference was also true for CD63+ PMP levels (281 x 10(6)/l, range 182-551, vs. 137 x 10(6)/l, range 64-432; p = 0.015). Conclusion: Climacteric lowers the level of PMP but has no impact on the number of EMP in women. These data suggest that PMP and EMP do not play a significant role in enhancing the risk of thrombotic events in healthy, postmenopausal women. Copyright (C) 2012 S. Karger AG, Base

ISTH guidelines for antithrombotic treatment in COVID-19

Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with coronavirus disease 2019 (COVID-19) may realize additional benefits from heparins. Optimal dosing and timing of these treatments and benefits of other antithrombotic agents remain unclear. In October 2021, ISTH assembled an international panel of content experts, patient representatives, and a methodologist to develop recommendations on anticoagulants and antiplatelet agents for patients with COVID-19 in different clinical settings. We used the American College of Cardiology Foundation/American Heart Association methodology to assess level of evidence (LOE) and class of recommendation (COR). Only recommendations with LOE A or B were included. Panelists agreed on 12 recommendations: three for non-hospitalized, five for non-critically ill hospitalized, three for critically ill hospitalized, and one for post-discharge patients. Two recommendations were based on high-quality evidence, the remainder on moderate-quality evidence. Among non-critically ill patients hospitalized for COVID-19, the panel gave a strong recommendation (a) for use of prophylactic dose of low molecular weight heparin or unfractionated heparin (LMWH/UFH) (COR 1); (b) for select patients in this group, use of therapeutic dose LMWH/UFH in preference to prophylactic dose (COR 1); but (c) against the addition of an antiplatelet agent (COR 3). Weak recommendations favored (a) sulodexide in non-hospitalized patients, (b) adding an antiplatelet agent to prophylactic LMWH/UFH in select critically ill, and (c) prophylactic rivaroxaban for select patients after discharge (all COR 2b). Recommendations in this guideline are based on high-/moderate-quality evidence available through March 2022. Focused updates will incorporate future evidence supporting changes to these recommendations

Serotonin transporter (SERT) and translocator protein (TSPO) expression in the obese ob/ob mouse

Background: An ever growing body of evidences is emerging concerning metabolism hormones, neurotransmitters or stress-related biomarkers as effective modulators of eating behavior and body weight in mammals. The present study sought at examining the density and affinity of two proteins related to neurotransmission and cell metabolism, the serotonin transporter SERT and the cholesterol import-benzodiazepine site TSPO (translocator protein), in a rodent leptin-lacking mutant, the obese ob/ob mouse. Binding studies were thus carried out in brain or peripheral tissues, blood platelets (SERT) and kidneys (TSPO), of ob/ob and WT mice supplied with a standard diet, using the selective radiochemical ligands [(3)H]-paroxetine and [(3)H]-PK11195. Results: We observed comparable SERT number or affinity in brain and platelets of ob/ob and WT mice, whilst a significantly higher [(3)H]-PK11195 density was reported in the brain of ob/ob animals. TSPO binding parameters were similar in the kidneys of all tested mice. By [(3)H]-PK11195 autoradiography of coronal hypothalamic-hippocampal sections, an increased TSPO signal was detected in the dentate gyrus (hippocampus) and choroids plexus of ob/ob mice, without appreciable changes in the cortex or hypothalamic-thalamic regions. Conclusions: These findings show that TSPO expression is up-regulated in cerebral regions of ob/ob leptin-deficient mice, suggesting a role of the translocator protein in leptin-dependent CNS trophism and metabolism. Unchanged SERT in mutant mice is discussed herein in the context of previous literature as the forerunner to a deeper biochemical investigation